Olema Pharmaceuticals, Inc. (OLMA) intrinsic value & 10-year financials
Olema Pharmaceuticals, Inc. (OLMA) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $6.58
- Market cap
- $572.5M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -30.4%
- Free cash flow (FY2025)
- —
OLMA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$162.5M | -$1.87 | — | — | -51.1% |
| FY2024 | — | -$129.5M | -$2.20 | -$104.5M | — | -62.3% |
| FY2023 | — | -$96.7M | -$2.14 | — | — | -58.0% |
| FY2022 | — | -$104.8M | -$2.62 | -$82.4M | — | -47.7% |
| FY2021 | — | -$71.1M | -$1.80 | -$52.3M | — | -26.0% |
| FY2020 | — | -$22.1M | -$3.42 | -$19.9M | — | -13.5% |
| FY2019 | — | -$4.3M | -$1.66 | — | — | 45.5% |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Olema Pharmaceuticals, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Olema Pharmaceuticals, Inc. has historically struggled to out-earn its cost of capital, averaging just -30.4% ROIC.
Olema Pharmaceuticals, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Olema Pharmaceuticals, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.